• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

ABBV STOCK HITS RECORD ALL TIME HIGH

Quote




















anonymous said:
YAWN who cares loser.
Click to expand...

Good comeback. Of course, what else would you say after making such a stupid previous comment. You're an idiot!!! It's troll like you that have diminished the effectiveness of what could be a useful & interesting chat message board. Go back to putting you 50 piece puzzle together.
 




anonymous said:
Good comeback. Of course, what else would you say after making such a stupid previous comment. You're an idiot!!! It's troll like you that have diminished the effectiveness of what could be a useful & interesting chat message board. Go back to putting you 50 piece puzzle together.
Click to expand...
Not funy. Our job responsibilities include promulgating the truth and defending our Leaders.
 




Let’s not kick sand in the sandbox kiddies. Please y’all must ditch the playground antics.Thanks. I see the stock didn’t bounce today.
Ricks Q4 Call showed a nervous man with much to hide. The statements are chock full of holes and lies. So another $5B in stock buybacks and stock tanks another 10%. Wild action on Wall Street with ABBV.
 




Watching the panic in C Suite is priceless. Greedy leeches are cashing out BIG TIME. Watching HEAVY insider selling going on. Current sell/buy ratio is 2.37. There were 11 sales on the open market in the last 12 weeks. They dumped 307,648 shares while purchases were only 129,690. This subtracted 5.4 million shares from insider’s bank, and the stock saw a -10.51 percent decline in value since the news became public. This transaction left 105.36 thousand shares in the EVP, Finance & Administration account. When it rains it pours for shareholders. It’s sunny skies for C Suite though.
 




anonymous said:
Not funy. Our job responsibilities include promulgating the truth and defending our Leaders.
Click to expand...

Corky, How the Hell did Rick dodge the massive $40+billion in Abbv debt during entire CC? The word was never used. Why didn’t the analysts bring this up? On Abbott Labs CC at least Miles addressed Abbott’s $23 billion and repeatedly expressed how ABT is repaying its debt to have the financial flexibility it needs. Rick has no plan. Funny but sad, he’s like the captain on the titanic, in shock, disoriented and staring into space while his ship goes down. Employees who stay, better get a life jacket real quick.
 




Which Abbvie Executives will appear voluntarily or forced to appear by subpoena?
Ricks got some Mansplaining to do!

Executives from seven pharmaceutical manufacturers will testify about drug pricing practices before the Senate Finance Committee "one way or another," Sen. Ron Wyden said Tuesday. Wyden and Sen. Chuck Grassley on Monday sent letters asking seven major drugmakers to testify at a Feb. 26 hearing, including AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
Calling the pace of drug price increases "unsustainable," Grassley said in a statement he wants pharmaceutical executives to explain how they price these treatments, "whether the status quo is unacceptable" and what can be done to lower costs.Wyden followed with a tweet Tuesday that stopped short of threatening to issue a subpoena, indicating that participation at the hearing isn't entirely voluntary. He said the companies "will come before the committee one way or another."
 




anonymous said:
Which Abbvie Executives will appear voluntarily or forced to appear by subpoena?
Ricks got some Mansplaining to do!

Executives from seven pharmaceutical manufacturers will testify about drug pricing practices before the Senate Finance Committee "one way or another," Sen. Ron Wyden said Tuesday. Wyden and Sen. Chuck Grassley on Monday sent letters asking seven major drugmakers to testify at a Feb. 26 hearing, including AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
Calling the pace of drug price increases "unsustainable," Grassley said in a statement he wants pharmaceutical executives to explain how they price these treatments, "whether the status quo is unacceptable" and what can be done to lower costs.Wyden followed with a tweet Tuesday that stopped short of threatening to issue a subpoena, indicating that participation at the hearing isn't entirely voluntary. He said the companies "will come before the committee one way or another."
Click to expand...

worst part is this is a bipartisan effort. left and right together can hurt this company bad.
 




CEO Kenny Frazier (whom I’ve met on several occasions) will personally testify for Merck. Kens is a stand up guy with a rags to riches story that’s quite amazing. Another CEO who remained anonymous will also testify. Will Rick man up and take the stand or let Bill Chase do his dirty work before he leaves? Abbvie Legal is already doing strategic research and coaching and role playing with Rick and others for potential appearance.
 




Ken is now joined by Merck, Pfizer, Sanofi and Bristol-Myers Squibb CEO’s! They are ALL testifying. AstraZeneca is reviewing request. Ricky along with JNJ have yet to RSVP to the committee's invite.

For starters Rick needs to be asked the following:

How does executive pay/compensation matrix relate to drug pricing?

Regarding he $15B stock buyback with Tax credit. What jobs were gained and what infrastructure (manufacturing plants, offices) in U.S.were constructed and where and at what cost?

Was there ever a discrepancy in the level of education attained by you on certain SEC FDA and other forms or filed documents NOT attributed to a clerical error?

What date were you briefed on the negative clinical data regarding Rova T?

What’s the status internally at Abbvie regarding California Commissioner Dave Jones complaint on behalf of the State of California against AbbVie Inc, alleging illegal kickbacks to healthcare providers to prescribe Humira.

What’s the status of FTC complaint against Abbvie for using strategies like pay for play to hinder or delay biosimilars from entering the market by Amgen and Samsung Bioepis?

European patients are already benefiting from significantly lower prices with biosimilar competition.Will Americans be without access to Humira biosimilars for almost 5 more years?

HR
 








anonymous said:
As shareholders we want regular reporting on how drug pricing risks are integrated into executive comp structures. Ricks salary needs to be decreased.

AbbVie Inc
NYSE: ABBV
$99.23 USD DOWN−0.40 (0.40%)
Click to expand...

Richard must answer this question. It’s a major concern of Congress along with Humira patent issue.
 








anonymous said:
Ken is now joined by Merck, Pfizer, Sanofi and Bristol-Myers Squibb CEO’s! They are ALL testifying. AstraZeneca is reviewing request. Ricky along with JNJ have yet to RSVP to the committee's invite.

For starters Rick needs to be asked the following:

How does executive pay/compensation matrix relate to drug pricing?

Regarding he $15B stock buyback with Tax credit. What jobs were gained and what infrastructure (manufacturing plants, offices) in U.S.were constructed and where and at what cost?

Was there ever a discrepancy in the level of education attained by you on certain SEC FDA and other forms or filed documents NOT attributed to a clerical error?

What date were you briefed on the negative clinical data regarding Rova T?

What’s the status internally at Abbvie regarding California Commissioner Dave Jones complaint on behalf of the State of California against AbbVie Inc, alleging illegal kickbacks to healthcare providers to prescribe Humira.

What’s the status of FTC complaint against Abbvie for using strategies like pay for play to hinder or delay biosimilars from entering the market by Amgen and Samsung Bioepis?

European patients are already benefiting from significantly lower prices with biosimilar competition.Will Americans be without access to Humira biosimilars for almost 5 more years?

HR
Click to expand...

Richard will testify. This is going to get interesting. Will congress give fluff question to please thier lobbyists and special interest donors or play hard ball?

The powerful Senate committee has invited seven drugmakers to testify. Merck & Co. and Pfizer were first to confirm attendance of their respective company heads, followed by Sanofi, Bristol-Myers Squibb and AbbVie. J&J will send the head of its pharmaceuticals division, while AstraZeneca is still reviewing the committee's request.
 












Top Bottom
Back
Quote